1. World Health Organization: Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle- income countries. 2011, Geneva, Switzerland: World Health Organization, 1-70.
2. Sarrazin H, Wilkinson KA, Andersson J, Rangaka MX, Radler L, Van Veen K, Lange C, Wilkinson RJ: Association between tuberculin skin test reactivity, the memory CD4 cell subset, and circulating FoxP3-expressing cells in HIV-infected persons. J Infect Dis. 2009, 199: 702-710. 10.1086/596735.
3. Centers for Disease Control and Prevention: Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR. 2000, 49 (RR6): 1-51.
4. Centers for Disease Control (CDC): Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR. 1989, 38: 236–8-243–50.
5. Cobelens FG, Egwaga SM, Van Ginkel T, Muwinge H, Matee MI, Borgdorff MW: Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis. 2006, 43: 634-639. 10.1086/506432.